#1 Clinical Trials Search in Europe

Myoviridae Bacteriophage Against Klebesiella Pneumoniae (169.802 Bp)

This article discusses a clinical trial investigating the use of a novel bacteriophage cocktail called TP-122A for treating ventilator-associated pneumonia (VAP). The study aims to assess the safety and tolerability of TP-122A when administered alongside standard care in adult patients with VAP. This Phase 1/2a trial represents an important step in exploring innovative treatments for this serious condition.

Table of Contents

What is MYOVIRIDAE BACTERIOPHAGE?

MYOVIRIDAE BACTERIOPHAGE AGAINST KLEBSIELLA PNEUMONIAE (169.802 BP) is a type of virus that specifically targets and kills the bacteria Klebsiella pneumoniae. It is part of a larger group of viruses called bacteriophages, or simply “phages,” which are viruses that infect and destroy bacteria[1]. This particular phage belongs to the Myoviridae family and has a genome size of 169,802 base pairs (BP).

In the clinical trial, this bacteriophage is referred to by its synonym Kle_F58/19. It is one component of a larger medication called TP-122, which is a cocktail of different bacteriophages designed to treat ventilator-associated pneumonia (VAP)[1].

Target Condition: Ventilator-Associated Pneumonia

Ventilator-Associated Pneumonia (VAP) is a serious lung infection that can occur in patients who are on mechanical ventilation in hospitals. It typically affects critically ill patients in intensive care units (ICUs). VAP occurs when bacteria enter the lungs of a person who is on a ventilator, causing inflammation and infection[1].

How It Works

MYOVIRIDAE BACTERIOPHAGE works by specifically targeting and destroying Klebsiella pneumoniae bacteria. Here’s a simple breakdown of how it functions:

  1. The bacteriophage attaches to the surface of the Klebsiella pneumoniae bacterium.
  2. It injects its genetic material into the bacterium.
  3. The phage’s genes hijack the bacterium’s cellular machinery to produce more phages.
  4. Eventually, the bacterium bursts open (lyses), releasing new phages that can infect other nearby bacteria.

This process continues until all the targeted bacteria are eliminated[1].

Clinical Trial Details

The MYOVIRIDAE BACTERIOPHAGE is being studied as part of a clinical trial for a medication called TP-122. This trial is a Phase 1/2a study, which means it’s one of the earliest stages of testing in humans. The main goals of this study are to assess the safety and tolerability of TP-122 in treating ventilator-associated pneumonia[1].

Key points about the trial:

  • It’s a randomized, open-label study, meaning participants are randomly assigned to either receive TP-122 or standard care, and both the patients and doctors know which treatment is being given.
  • The medication is given through nebulization (inhaled as a mist) every 8 hours for 7 days.
  • The study is looking at adult patients (18 years or older) with ventilator-associated pneumonia.
  • Patients must have a confirmed Pseudomonas aeruginosa infection in their lower respiratory tract to be eligible for the study[1].

Potential Benefits

While the effectiveness of this treatment is still being studied, potential benefits may include:

  • Targeted treatment of antibiotic-resistant bacteria
  • Reduced use of traditional antibiotics, potentially slowing the development of antibiotic resistance
  • Possible reduction in the duration of mechanical ventilation
  • Potential decrease in ICU stay duration
  • Improved survival rates for patients with ventilator-associated pneumonia[1]

Safety Considerations

As this is an early-stage clinical trial, the safety profile of TP-122 (including the MYOVIRIDAE BACTERIOPHAGE) is still being established. The study will closely monitor for any adverse events or side effects. Some general considerations include:

  • The treatment is not recommended for pregnant or breastfeeding women.
  • Patients with certain conditions such as severe asthma, reactive airway disease, or who are immunocompromised are excluded from the trial.
  • The study will monitor vital signs, electrocardiogram (ECG) readings, and laboratory parameters to ensure patient safety[1].

Conclusion

MYOVIRIDAE BACTERIOPHAGE AGAINST KLEBSIELLA PNEUMONIAE (169.802 BP) represents an innovative approach to treating ventilator-associated pneumonia. As part of the TP-122 bacteriophage cocktail, it offers a targeted method to combat bacterial infections, potentially providing an alternative to traditional antibiotics. While the research is still in its early stages, this treatment holds promise for improving outcomes for critically ill patients with VAP. As always, patients should consult with their healthcare providers about the most appropriate treatment options for their individual situations[1].

Aspect Details
Study Type Randomized, Parallel, Open-Label, Phase 1/2a
Intervention TP-122A (bacteriophage cocktail) administered by nebulization
Target Condition Ventilator-Associated Pneumonia (VAP)
Primary Objective Evaluate safety and tolerability of TP-122A
Secondary Objectives Assess clinical cure, microbiological response, mechanical ventilation duration, ICU stay, and survival
Key Inclusion Criteria Adults with VAP, stable ventilatory requirements, P. aeruginosa infection
Key Exclusion Criteria Recent cancer treatment, severe asthma, immunocompromised status
Treatment Duration 7 days
Follow-up Period Two follow-up assessments (FUp1 and FUp2)

FAQ

  • What is TP-122A? TP-122A is a bacteriophage cocktail containing various types of bacteriophages that target specific bacteria, including Klebsiella pneumoniae and Pseudomonas aeruginosa. It is being studied as a potential treatment for ventilator-associated pneumonia.
  • What is the main goal of this clinical trial? The primary objective of this study is to evaluate the safety and tolerability of multiple doses of TP-122A when administered by nebulization every 8 hours for 7 days, in addition to standard care, in adult subjects with ventilator-associated pneumonia.
  • Who can participate in this clinical trial? Participants must be 18 years or older, diagnosed with ventilator-associated pneumonia, have stable ventilatory requirements, and a microbiological diagnosis of P. aeruginosa infection in the lower respiratory tract. There are additional inclusion and exclusion criteria that the study team will assess.
  • How is TP-122A administered in this trial? TP-122A is administered through nebulization, which means it is inhaled as a mist. Participants receive multiple doses every 8 hours for 7 days, in addition to standard care for ventilator-associated pneumonia.
  • What outcomes will the researchers measure? The researchers will assess various outcomes, including adverse events, changes in clinical laboratory parameters, vital signs, and electrocardiogram results. They will also evaluate the proportion of patients achieving clinical cure, time to clinical cure, microbiological response, duration of mechanical ventilation, length of ICU stay, and survival rates.

Ongoing Clinical Trials on Myoviridae Bacteriophage Against Klebesiella Pneumoniae (169.802 Bp)

  • Safety and tolerability study of bacteriophage cocktail TP-122A given by inhalation in adults with ventilator-associated pneumonia

    Not yet recruiting

    2 1 1
    Investigated drugs:
    The Netherlands Portugal

  • Study on the Safety and Tolerability of TP-122 for Treating Ventilator-Associated Pneumonia in Adults

    Not yet recruiting

    2 1 1
    Investigated drugs:
    France

Glossary

  • Ventilator-Associated Pneumonia (VAP): A type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals. It typically develops more than 48 hours after a patient has been intubated.
  • Bacteriophage: A virus that infects and replicates within bacteria. Bacteriophages are being studied as potential alternatives to antibiotics for treating bacterial infections.
  • Nebulization: The process of converting a liquid into a fine spray or mist, often used to administer medications directly to the lungs through inhalation.
  • Standard of Care (SoC): The currently accepted method of treating a particular condition, based on scientific evidence and expert consensus.
  • Clinical Cure: The resolution or significant improvement of signs and symptoms related to the infection, without the need for additional antibiotic therapy.
  • Microbiological Response: The elimination or reduction of the bacteria causing the infection, as determined by laboratory tests.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
  • Serious Adverse Event (SAE): An adverse event that results in death, is life-threatening, requires hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.
  • Electrocardiogram (ECG): A test that measures the electrical activity of the heart, used to detect various heart conditions and monitor heart health.
  • Intensive Care Unit (ICU): A specialized hospital unit that provides intensive care medicine, treating patients with severe or life-threatening illnesses and injuries that require constant care and close monitoring.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-tolerability-of-tp-122-for-treating-ventilator-associated-pneumonia-in-adults/